Prostate cancer Active Surveillance Study (PASS) Cohort: Infrastructure Support for Cancer Research

项目摘要/摘要 我们建议支持已建立的前列腺癌主动监测研究(PASS)队列，这是一个 选择活动的临床局限性前列腺癌患者的大型多机构队列 监控以控制他们的癌症。具有广泛的资格标准，旨在代表男性人口 利用主动监测，该队列有超过2100名参与者，具有广泛的临床和 流行病学数据(人口、生活方式、生活质量、长期结果)和纵向生物样本 (生殖系DNA、血清、血浆、尿液和前列腺组织)根据标准化方案收集。这个 Cohort成立于2008年，是为了应对前列腺癌过度治疗的越来越多证据和 需要一项前瞻性研究来发现和验证前列腺癌进展的生物标记物，并 确定癌症进展和患者预后的决定因素。在过去的十年里，这群人 积累了丰富的数据和生物样本，因此它可以作为解决关键问题的基础 与早期前列腺癌最佳个性化治疗相关的问题。 这项申请的成功资助将支持PASS的强大基础设施，这反过来将确保 PASS数据和样本的可用性，以促进对癌症决定因素的研究 进展、复发和结果。这些研究工作中有很大一部分是 包括在目前资助的联邦赠款中，以及成功完成目前和未来的 项目有赖于PASS企业的持续成功。这一群体的影响在于它有可能 调查最重要的研究问题：确定更好的前列腺癌预后标志物 癌症侵袭性；了解早期的临床处理、进展和结果 前列腺癌；根据个人特征量身定做主动监测方法 偏好；描述临床病理因素、患者生活方式和疾病之间的关系 生物学；开发向患者传达医疗信息的新工具；以及理解决策-- 在患者中进行积极的监测，特别是在生活质量、焦虑和后悔方面。 这些变革性研究工作的成功完成将在最大程度上解决未得到满足的需求 普遍诊断为男性癌症，大大减轻了当前公共卫生的早期负担 前列腺癌。

PROJECT SUMMARY/ABSTRACT We propose to support the established Prostate cancer Active Surveillance Study (PASS) cohort, which is a large multi-institutional cohort of men with clinically localized prostate cancer who have elected active surveillance to manage their cancer. With broad eligibility criteria designed to represent the population of men who utilize active surveillance, the cohort has over 2,100 participants with extensive clinical and epidemiological data (demographic, lifestyle, quality of life, long-term outcomes) and longitudinal biospecimens (germline DNA, serum, plasma, urine, and prostate tissue) collected according to a standardized protocol. The cohort was established in 2008 in response to the growing evidence of prostate cancer overtreatment and the need for a prospective study to discover and validate biomarkers of prostate cancer progression, and to identify determinants of cancer progression and patient outcomes. Over the past decade, the cohort has amassed a wealth of data and biospecimens so that it serves as the foundation for addressing critical questions relevant to the optimal personalized management of early stage prostate cancer. The successful funding of this application will support a robust infrastructure for PASS that in turn will ensure the availability of PASS data and specimens to facilitate research addressing determinants of cancer progression, recurrence, and outcomes. A substantial proportion of these research endeavors are encompassed in currently funded federal grants, and the successful completion of the current and future projects relies on the continued success of the PASS enterprise. The impact of this cohort lies in its potential to investigate research questions of paramount importance: to identify better prognostic markers of prostate cancer aggressiveness; to understand the clinical management, progression and outcomes of early stage prostate cancer; to tailor the approach of active surveillance based on individual characteristics and preferences; to characterize associations between clinicopathologic factors, patient lifestyle, and disease biology; to develop new tools to communicate medical information to patients; and to understand decision- making among patients on active surveillance, in particular with regards to quality of life, anxiety, and regret . The successful completion of these transformative research endeavors will address unmet needs in the most commonly diagnosed male cancer and substantially reduce the current public health burden of early stage prostate cancer.